Welcome to our dedicated page for Utime news (Ticker: WTO), a resource for investors and traders seeking the latest updates and insights on Utime stock.
UTime Limited (Nasdaq: WTO) is a consumer electronics and mobile communications company whose news flow centers on mobile devices, smart wearables and health technology. The company publicly describes its business as designing, developing, manufacturing and selling smartphones, feature phones, accessories and smart wearable devices, while also providing OEM/ODM and Electronics Manufacturing Services for other brands. Its press releases and Form 6-K filings provide insight into product launches, strategic partnerships, capital markets activity and corporate governance developments.
Recent UTime news has highlighted the launch of health-focused smartwatches with integrated blood pressure monitoring and smart rings designed for sleep and continuous health monitoring. The company has also reported active promotion of these smart wearable devices into international markets through existing distribution channels and partner networks. Another recurring theme in UTime’s announcements is its exploration of AI-based health data analysis models that use continuous physiological data from its devices to provide users with health trend insights and risk management references.
Investors and observers following WTO news will also find updates on strategic agreements and financing. UTime has disclosed a Memorandum of Understanding to co-develop a digital platform for elderly care services with Hainan Fuxinyi Investment Co., Ltd., as well as a smart health device procurement agreement with Tumu Vertex LLC involving an initial order for 50,000 medical-grade smart wearable devices. Capital markets news includes registered direct and best-efforts offerings under a shelf registration statement, and announcements related to Nasdaq listing requirements and a 1-for-100 reverse stock split.
In addition, UTime’s news feed covers board and management changes, governance statements and responses to unauthorized communications. For readers tracking WTO, this page brings together product, partnership, financing and governance announcements in one place, allowing a structured view of how the company describes its strategy in mobile devices and health-oriented smart wearables.
UTime (Nasdaq: WTO) announced a 5-for-1 reverse stock split of its Class A ordinary shares, effective 8:00 a.m. ET on February 17, 2026.
The Company will trade on the Nasdaq Capital Market post-split under the existing ticker WTO with a new CUSIP G9411M140. The board approved the consolidation on January 20, 2026, shareholders ratified it at the January 26, 2026 extraordinary meeting, and related amendments to authorized share capital and the memorandum and articles were approved.
The consolidation will not change any shareholder’s percentage ownership except for minor adjustments from fractional-share treatment.
UTime (Nasdaq: WTO) reported that its Shenzhen subsidiary, Shenzhen Liandai, entered an Intentional Order Cooperation Agreement with Shenzhen Yunwei Digital for the potential supply of 500,000 GM800 smart servers, representing an estimated contract value of approximately US$50 million.
The GM800 is configured with an RK3566 chipset, 4GB RAM and 128GB storage. The agreement targets formal contract signing by mid-February 2026 and initial deliveries beginning by mid-February 2026, with performance continuing through 2027.
UTime (Nasdaq: WTO) announced that its Hong Kong subsidiary signed a commercial sales agreement worth nearly $10 million with Denver-based Tumu Vertex LLC for an initial purchase order of 50,000 smart health devices.
The order is described as 25,000 units of the UT-168 BT Blood Pressure Watch and 25,000 units of the UR08 ECG Smart Ring, with FOB Hong Kong delivery, phased payments, joint quality-control procedures, and first deliveries starting in Q1 2026. UTime highlights FDA-certified medical-grade monitoring integrated into everyday wearables and positions the deal as a strategic entry into the North American medical-grade wearable market.
UTime (Nasdaq: WTO) announced a 1-for-100 reverse stock split of its Class A ordinary shares, effective 12:01 a.m. ET on November 21, 2025. Shares will trade on a split-adjusted basis at market open on November 21, 2025 under the ticker WTO. The company said the reverse split is intended to increase the per-share trading price to help regain compliance with Nasdaq's minimum bid price requirement and to better position the stock for long-term growth and institutional participation.
No fractional shares will be issued; any fractional share resulting from the adjustment will be rounded up to the nearest whole share. Brokerages and book-entry positions will be automatically updated to reflect the reverse split.
UTime Limited (Nasdaq: WTO) said on Nov 5, 2025 that it is expanding distribution of its health-focused smart wearables to additional international markets through existing global channels and partners.
The company plans to leverage its mobile-device experience in supply chain management and product development to introduce newly launched smartwatches and smart rings overseas, targeting markets where it already has business connections and seeking new partnerships.
Management emphasized the products' combination of functional design and cost-effectiveness as competitive advantages for gaining share in international personal-health markets.
UTime (Nasdaq: WTO) announced ongoing research into applying AI to health data analysis from wearable devices on November 3, 2025. The company is developing AI algorithm models to analyze continuous physiological signals from smart watches and rings.
Key research directions include building hypertension risk assessment models that integrate blood pressure, heart rate, activity and sleep, and conducting cardiovascular trend assessments via pulse wave morphology analysis. UTime says these AI functions are intended as health insights and risk-management references, not medical diagnoses. Management framed the work as a long-term R&D investment to generate earlier, deeper user health insights.
UTime Limited (Nasdaq: WTO) on October 30, 2025 released a smart ring designed for unobtrusive nighttime and long‑term continuous health monitoring.
The ring measures skin temperature, SpO2, respiratory rate, and heart rate variability (HRV) and targets sleep quality assessment with detailed, unobtrusive sleep analysis reports. It also supports daily activity tracking and female health cycle management. Management described the ring as a complementary, discreet alternative to smartwatches for continuous monitoring in specific scenarios.
UTime (Nasdaq: WTO) launched a smartwatch with integrated blood pressure monitoring on Oct 28, 2025, expanding its health tech product lineup.
The device uses the oscillometric method with an integrated micro air pump and high-precision pressure sensor, and it holds a China NMPA Class II Medical Device Registration (Registration Certificate No. Guangdong Instrument Note No. 20162070928). The watch also reports heart rate, blood oxygen saturation, sleep analysis, and multiple sports modes while emphasizing wearing comfort and interactive features like voice reminders.
UTime (NASDAQ: WTO) announced an October 23, 2025 Memorandum of Understanding to co-develop a digital eldercare services platform with Hainan Fuxinyi Investment over a three-year collaboration.
Under the MOU UTime will provide device design, product development and manufacturing; Fuxinyi will integrate eldercare service providers and community resources. A pilot rollout is planned in Nanning, Guangxi province with phased expansion across southern China. The company frames the MOU as a strategic shift from consumer devices toward healthcare and the "silver economy" to pursue long-term growth opportunities.
UTime (Nasdaq: WTO) priced a registered direct offering of 22,727,275 units at $1.10 per unit, each unit comprising one Class A ordinary share and one Series A warrant. Gross proceeds are expected to be approximately $25.0 million before placement agent fees and expenses. Each Warrant is immediately exercisable at $1.10 and expires six months after issuance. The offering is expected to close on or about October 17, 2025, subject to customary conditions, and is being placed by Univest Securities under a Form F-3 shelf registration declared effective June 10, 2024.